Precision Radiation Therapy to Treat Prostate Cancer Spread Safe for High-Risk Patients, Phase 2 Trial Finds

Precision Radiation Therapy to Treat Prostate Cancer Spread Safe for High-Risk Patients, Phase 2 Trial Finds
Prostate cancer patients at a high risk of tumor spreading can safely receive high-dose radiation therapy that targets both the prostate and neighboring pelvic lymph nodes, a Phase 2 trial shows. Trial findings were published in the study, “Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL),” in the International Journal of Radiation Oncology*Biology*Physics. While most men with newly diagnosed prostate cancer have localized disease, a significant proportion of them are at risk of their disease spreading to the lymph nodes in the pelvis. While the treatment of choice for these patients is androgen deprivation therapy and radiation to the prostate, studies in breast cancer patients suggest that radiation to the surrounding lymph nodes could increase survival outcomes. However, this type of therapy can lead to side effects, such as gastrointestinal (GI) toxicity and incontinence, and whether this approach could be safely delivered to prostate cancer patients was not previously known. “Radiotherapy to the pelvic lymph nodes using traditional methods can often result in unpleasant side-effects for the patient in the form of bladder and bowel problems,”
Subscribe or to access all post and page content.